Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Studiet fortsætter nu i sin anden del, som forventes afsluttet senere i 2024.ALK indsender protokolændring for at udvide studiet til et fase 1-2 effektstudie. ALK (ALKB:DC / OMX: ALK B / AKBLF)...
-
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B /...
-
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii – The Danish, pharmaceutical company ALK (ALKB:DC /...
-
Finanskalender 2024 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11. januar 2024: Stilleperiode8. februar 2024: Offentliggørelse af årsrapport 202314. marts 2024 kl. 16.00: Ordinær generalforsamling...
-
2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period 8 February 2024: Annual report 2023 14 March 2024 at 4.00 p.m.: Annual...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
-
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led...
-
ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første ni måneder (Q3) 2023 onsdag den 15. november 2023. ALK afholder samme dag kl. 13.30 (CET) en telekonference for investorer...